News
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...
Novo Nordisk experiences heightened competition from copycat versions of its Wegovy obesity drug, affecting its market share, ...
Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback